Jefferies Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $40
Yarrow Bioscience Reports Third Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience Q3 EPS $(0.43) Misses $(0.32) Estimate
Guggenheim starts Yarrow Bioscience at Buy, citing Graves’ disease potential
Guggenheim Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $60
Yarrow Bioscience Announces Participation in November Investor Events
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Reported Earlier, Yarrow Bioscience Prices $150M Underwritten Public Offering Of 5,769,231 Shares At $26.00 Per Share
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience Launches Underwritten Public Offering To Fund Pipeline Development And Corporate Operations; No Terms Disclosed
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience Q2 EPS $(2.14) Misses $(0.22) Estimate
BTIG Initiates Coverage On Yarrow Bioscience with Buy Rating, Announces Price Target of $58
TD Cowen Initiates Coverage On Yarrow Bioscience with Buy Rating
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease
Yarrow Bioscience And VYNE Therapeutics Compete Merger With Previously Announced Private Financings Totaling ~$200M; To Operate As Yarrow Bioscience And Trade On Nasdaq Capital Market From July 28 Under Ticker Symbol 'YARW'
VYNE Therapeutics Announces 1-For-50 Reverse Stock Split, Effective July 24
VYNE Therapeutics Announces Special Cash Dividend Of $0.38/Share
VYNE Therapeutics Q1 EPS $(0.08) Beats $(0.18) Estimate, Sales $86.000K Miss $200.000K Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.